Regulators discuss "critical issues" in dementia R&D at Rome meeting
This article was originally published in Scrip
Executive Summary
Regulators and academics are meeting in Rome today and tomorrow to discuss ways of improving the diagnosis and treatment of dementia, with the focus on aspects such as clinical trial design, endpoints and benefit-risk balance, and the possibility of expedited drug approval procedures.